TAKE A LOOK AT WHICH REPORT YOUR PORTFOLIO'S BEEN MISSING...

Shareholders Foundation offers real-time reporting of class action exposure on a per transaction basis,
including the documents you will need for claim filing and settlement recovery.
Start Monitoring Your Investments

Puma Biotechnology Inc (NYSE:PBYI) Investor Investigation Concerning Potential Violations Of Securities Laws Announced

  • If you purchased shares of Puma Biotechnology Inc (NYSE:PBYI), you have certain options and you should contact the Shareholders Foundation, Inc.

  • To have your information reviewed for options and to receive notifications about this case, please use this form. You may also send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.

Investigation Overview

December 5, 2014 (Update) - On July 22, 2014, Puma Biotechnology Inc announced positive top line results from the Phase III clinical trial of Puma's investigational breast cancer drug, PB272 (neratinib). Puma Biotechnology Inc said that based on the results from the ExteNET study, Puma plans to file for regulatory approval of neratinib in the extended adjuvant setting in the first hal...



You must register (for free) or login to view the entire investigation.

Click here to Sign In or Register (for a free account)

@screen width:
@theme:
@breakpoints:
@layout: